Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3345-3348

  Ansaldi, Filippo ^a   Canepa, Paola ^a   Parodi, Valentina ^a   Bacilieri, Sabrina ^a   Orsi, Andrea ^a   Compagnino, Federica ^a   Icardi, Giancarlo ^a   Durando, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antigenic drift; Cross protection; Oil in water adjuvants

Indexed keywords

AS VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OIL; SUBUNIT VACCINE; UNCLASSIFIED DRUG; WATER;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CROSS REACTION; DRUG EFFECT; EMULSION; FERRET; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H3N2; METAMORPHOSIS; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIROGENESIS; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; HUMANS; INFLUENZA VACCINES; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; POLYSORBATES; SQUALENE; VACCINATION;

EID: 67349145958     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.081     Document Type: Article

References (29)

1. Atassi M.Z., and Webster R.G. Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin. Proc Natl Acad Sci USA 80 3 (1983) 840-844
2. Ferguson N.M., Galvani A.P., and Bush R.M. Ecological and immunological determinants of influenza evolution. Nature 422 6930 (2003) 428-433
3. Hay A.J., Gregory V., Douglas A.R., and Lin Y.P. The evolution of human influenza viruses. Philos Trans R Soc Lond B: Biol Sci 356 1416 (2001) 1861-1870
4. Carrat F., and Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25 39-40 (2007) 6852-6862
5. Yamashita M., Krystal M., Fitch W.M., and Palese P. Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. Virology 163 1 (1988) 112-122
6. Nerome R., Hiromoto Y., Sugita S., Tanabe N., Ishida M., Matsumoto M., et al. Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism. Arch Virol 143 8 (1998) 1569-1583
7. Shaw M.W., Xu X., Li Y., Normand S., Ueki R.T., Kunimoto G.Y., et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303 10 (2002) 1-8
8. World Health Organization. Available on line at: http://www.who.int/csr/disease/influenza/influenzanetwork/en/index.html.
9. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26 12 (2008) 1525-1529
10. World Health Organization. Recommendations for influenza vaccines; 2008. Available online at: http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/index.html.
11. de Jong J.C., Beyer W.E., Palache A.M., Rimmelzwaan G.F., and Osterhaus A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61 1 (2000) 94-99
12. Del Giudice G., Hilbert A.K., Bugarini R., Minutello A., Popova O., Toneatto D., et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24 16 (2006) 3063-3065
13. Kojimahara N., Maeda A., Kase T., and Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 24 33-34 (2006) 5966-5969
14. Ansaldi F., Bacilieri S., Banfi F., Durando P., Sticchi L., Icardi G., et al. Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin Vaccine Immunol 13 1 (2006) 162-164
15. Legrand J., Vergu E., and Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24 44-46 (2006) 6605-6611
16. Doherty P.C., and Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 118 10 (2008) 3273-3275
17. Keitel W.A., Atmar R.L., Cate T.R., Petersen N.J., Greenberg S.B., Ruben F., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 166 (2006) 1121-1127
18. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., and Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 4 (2007) 659-663
19. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105 30 (2008) 10501-10506
20. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 17-19 (2001) 2673-2680
21. Squarcione S., Sgricia S., Biasio L.R., and Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21 11-12 (2003) 1268-1274
22. Baldo V., Baldovin T., Floreani A., Carraro A.M., Trivello R., and Family Medicine Group of Pianiga. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25 20 (2007) 3955-3961
23. Baldo V., Baldovin T., Floreani A., Fragapane E., Trivello R., and Family Medicine Group. Response of influenza vaccines against heterovariant influenza virus strains inadults with chronic diseases. J Clin Immunol 27 5 (2007) 542-547
24. Leroux-Roels I. Reactogenicity and safety of adjuvanted influenza vaccines administered in elderly. Influenza. Vaccines for the World; 2006. Study ID Flu-AS25-003, NCT: 00318149. Poster Presentation 12.
25. Zambon M. Laboratory diagnosis of influenza. In: Nicholson K.G., Webster R.G., and Hay A.J. (Eds). Textbook of influenza (1998), Blackwell Science, Oxford 291-313
26. Iorio A.M., Neri M., Lepri E., Camilloni B., Basileo M., Sigismondi N., et al. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinatedpeople living in a nursing home. Vaccine 24 44-46 (2006) 6615-6619
27. Moss P. Cellular immune responses to influenza. Dev Biol (Basel) 115 (2003) 31-37
28. Johansson B.E., and Brett I.C. Changing perspective on immunization against influenza. Vaccine 25 16 (2007) 4056-4063
29. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943